XL-228
As of the edition of 20 October 2026, XL-228 is a small molecule: stopped in 2011; acts on ABL1, BLK and FGR and 8 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2011
- Kind
- Small molecule
- Registered trials
- 2, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
11 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product11 company-target rows are on route A because of XL-228.
See the 11 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ABL1 | Tyrosine-protein kinase ABL1 | P00519 |
| LCK | Tyrosine-protein kinase Lck | P06239 |
| FYN | Tyrosine-protein kinase Fyn | P06241 |
| YES1 | Tyrosine-protein kinase Yes | P07947 |
| LYN | Tyrosine-protein kinase Lyn | P07948 |
| HCK | Tyrosine-protein kinase HCK | P08631 |
| FGR | Tyrosine-protein kinase Fgr | P09769 |
| SRC | Proto-oncogene tyrosine-protein kinase Src | P12931 |
| FRK | Tyrosine-protein kinase FRK | P42685 |
| BLK | Tyrosine-protein kinase Blk | P51451 |
| SRMS | Tyrosine-protein kinase Srms | Q9H3Y6 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Exelixis | Lead sponsor of trials | 2007 to now |